SCHEMBL2476938

SCHEMBL2476938

CC(C)(C)Cc1cccc(CC(C)(C)C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.41
CCR4 P51679 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
PGK1 P00558 1/20 0.38
PGK2 P07205 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
ESR1 P03372 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
CXCR4 P61073 2/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12776106 0.89 KCNH2 (0.38) KCNH2CCR4NPSR1PGK1PGK2
SCHEMBL14592944 0.89 CCR1 (0.40) KCNH2CCR4NPSR1PGK1PGK2
SCHEMBL14211895 0.87 KCNH2 (0.42) KCNH2CCR4NPSR1PGK1PGK2
SCHEMBL19891695 0.87 KCNH2 (0.52) KCNH2CCR4NPSR1GRIN2DGRIN3B
SCHEMBL21533982 0.87 KCNH2 (0.38) KCNH2CCR4NPSR1PGK1PGK2
SCHEMBL1912681 0.86 MEN1 (0.47) CCR4NPSR1GRIN2BNOS2MEN1
SCHEMBL21100036 0.85 GABRA1 (0.35) KCNH2CCR4NPSR1PGK1PGK2
SCHEMBL11955022 0.84 CYP3A4 (0.42) KCNH2CCR4GRNSORT1GAA
SCHEMBL10014000 0.84 CCR4 (0.36) KCNH2CCR4ESR1GRNSORT1
SCHEMBL4403139 0.84 MBOAT4 (0.36) KCNH2CCR4ESR1GRNSORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154984-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2017-04-19 EP claimed
WO-2015191437-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2015-12-17 WO claimed
EP-1146887-A4 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME UNIV PRINCETON (US) 2003-05-07 EP claimed
WO-2000041710-A9 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME UNIV PRINCETON (US) 2001-11-22 WO claimed
EP-1146887-A1 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME Princeton University (US) 2001-10-24 EP claimed
WO-2000041710-A1 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME PRINCETON UNIVERSITY (US) 2000-07-20 WO claimed
EP-4729508-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA Arcus Biosciences, Inc. (US) 2026-04-22 EP disclosed
US-20250214930-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. (US) 2025-07-03 US disclosed
US-12103907-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha ARCUS BIOSCIENCES, INC. (US) 2024-10-01 US disclosed
US-20240254079-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. 2024-08-01 US disclosed
US-20230399361-A1 MACROCYCLIC PEPTIDES UNIVERSITY OF NOTRE DAME DU LAC 2023-12-14 US disclosed
US-11787762-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha ARCUS BIOSCIENCES, INC. (US) 2023-10-17 US disclosed
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-07-06 US disclosed
EP-1179011-A1 GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME Princeton University (US) 2002-02-13 EP disclosed
WO-2000041710-A9 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME UNIV PRINCETON (US) 2001-11-22 WO disclosed
EP-1146887-A1 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME Princeton University (US) 2001-10-24 EP disclosed
EP-1095058-A1 GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME Princeton University (US) 2001-05-02 EP disclosed
WO-2000069892-A1 GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME PRINCETON UNIVERSITY (US) 2000-11-23 WO disclosed
WO-2000041710-A1 GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME PRINCETON UNIVERSITY (US) 2000-07-20 WO disclosed
WO-2000004044-A1 GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME PRINCETON UNIVERSITY (US) 2000-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF FIBP, FN1, TPX2 KCNH2 4733/4885CCR4 638/4885NPSR1 1376/4885
US-20250214930-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA HIF1AN, HIF1A, EGLN2 KCNH2 4270/4885CCR4 1746/4885NPSR1 3877/4885
US-20240254079-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA HIF1AN, HIF1A, EGLN2 KCNH2 4270/4885CCR4 1746/4885NPSR1 3877/4885
US-11787762-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha HIF1AN, HIF1A, EGLN2 KCNH2 4270/4885CCR4 1746/4885NPSR1 3877/4885
US-12103907-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha HIF1AN, HIF1A, EGLN2 KCNH2 4270/4885CCR4 1746/4885NPSR1 3877/4885
US-20230399361-A1 MACROCYCLIC PEPTIDES APP, MAPT, NEFM KCNH2 4698/4885CCR4 4387/4885NPSR1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.